Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use

Karl Åkerman, Christian C. Jansson, Jyrki (P) Kukkonen, Juha-Matti Savola, Siegfried Wurster, Victor Cockcroft

Research output: PatentScientific

Abstract

Abstract
The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic &#x0b31-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic &#x0b31-2 receptors, such as obesity, a withdrawal symptom to an adrenergic &#x0b31-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic &#x0b31-2 receptors. The pharmaceutical composition is preferably transdermal.
Original languageEnglish
Publication Year30 Nov 1999
Publication statusPublished - 30 Nov 1999
MoE publication typeH1 Granted patent

Cite this

Åkerman, K., Jansson, C. C., Kukkonen, J. P., Savola, J-M., Wurster, S., & Cockcroft, V. (1999). IPC No. A61K 031/415. Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use. (Patent No. 5,994,384).
Åkerman, Karl (Author) ; Jansson, Christian C. (Author) ; Kukkonen, Jyrki (P) (Author) ; Savola, Juha-Matti (Author) ; Wurster, Siegfried (Author) ; Cockcroft, Victor (Author). / Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use. IPC No.: A61K 031/415. Patent No.: 5,994,384. Nov 30, 1999.
@misc{04efa39bd2a84041837461fc82b0b013,
title = "Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use",
abstract = "Abstract The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic &#x0b31-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic &#x0b31-2 receptors, such as obesity, a withdrawal symptom to an adrenergic &#x0b31-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic &#x0b31-2 receptors. The pharmaceutical composition is preferably transdermal.",
author = "Karl {\AA}kerman and Jansson, {Christian C.} and Kukkonen, {Jyrki (P)} and Juha-Matti Savola and Siegfried Wurster and Victor Cockcroft",
year = "1999",
month = "11",
day = "30",
language = "English",
type = "Patent",
note = "5,994,384; A61K 031/415",

}

Åkerman, K, Jansson, CC, Kukkonen, JP, Savola, J-M, Wurster, S & Cockcroft, V Nov. 30 1999, Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use, Patent No. 5,994,384, IPC No. A61K 031/415.

Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use. / Åkerman, Karl; Jansson, Christian C.; Kukkonen, Jyrki (P); Savola, Juha-Matti; Wurster, Siegfried; Cockcroft, Victor.

IPC No.: A61K 031/415. Patent No.: 5,994,384. Nov 30, 1999.

Research output: PatentScientific

TY - PAT

T1 - Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use

AU - Åkerman, Karl

AU - Jansson, Christian C.

AU - Kukkonen, Jyrki (P)

AU - Savola, Juha-Matti

AU - Wurster, Siegfried

AU - Cockcroft, Victor

PY - 1999/11/30

Y1 - 1999/11/30

N2 - Abstract The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic &#x0b31-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic &#x0b31-2 receptors, such as obesity, a withdrawal symptom to an adrenergic &#x0b31-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic &#x0b31-2 receptors. The pharmaceutical composition is preferably transdermal.

AB - Abstract The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic &#x0b31-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic &#x0b31-2 receptors, such as obesity, a withdrawal symptom to an adrenergic &#x0b31-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic &#x0b31-2 receptors. The pharmaceutical composition is preferably transdermal.

M3 - Patent

M1 - 5,994,384

Y2 - 1999/11/30

ER -

Åkerman K, Jansson CC, Kukkonen JP, Savola J-M, Wurster S, Cockcroft V. Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use. A61K 031/415. 1999 Nov 30.